Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M

Evofem Biosciences, Inc.

2026-Q1 EPS reported -$0.04 revenue$899,000

Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.
Net sales $0.9M, up ~12.5% from $0.8M in Q1 2025; driven by higher WAC and improved gross-to-net.
Operating expenses $5.5M after excluding a one-time $5.6M R&D reduction from trade payables settlement.
Entered distribution agreement for SOLOSEC in Sub-Saharan Africa with Clovis Davis Pharmaceuticals.
UAE regulatory review ongoing; pricing certificates for PHEXX obtained; NIH-funded Phase 4 trial enrolling patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evofem Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue $0.9 million, net income $5.5 million, EPS $(0.04) per basic and diluted share.

Period: the three months ended March 31, 2026
Revenue: $0.9 million
Net income: $5.5 million
EPS: $(0.04) per basic and diluted share
Result: reported results

Exact text from the filing

For the three months ended March 31, 2026, net sales were $0.9 million

View on SEC.gov

Browse all earnings releases →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-024095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.